Drug intelligence / Profile preview

allogeneic human umbilical cord tissue-derived mesenchymal stem cells

Development stage: Phase 2
Lead developer: Novo Cellular Medicine Institute
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Allogeneic human umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) are an investigational cell therapy developed by Novo Cellular Medicine Institute LLP for the treatment of relapsing-remitting multiple sclerosis (RRMS). These cells are harvested from the Wharton's jelly of umbilical cord tissue and are characterized by their potent immunomodulatory, anti-inflammatory, and potentially neuroprotective properties. In RRMS, UC-MSCs are hypothesized to suppress the aberrant autoimmune response by modulating the activity of T-cells and B-cells and secreting paracrine factors that promote an environment conducive to neural repair and remyelination. This specific therapeutic product was evaluated in a Phase I/II clinical trial (NCT01531062) in combination with "liberation therapy," a percutaneous transluminal angioplasty procedure intended to treat chronic cerebrospinal venous insufficiency (CCSVI).

Other names: allogeneic human umbilical cord tissue-derived mesenchymal stem cells-Novo Cellular Medicine Institute LLP-relapsing-remitting multiple sclerosisUC-MSCumbilical cord-derived mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cells

Beyond the preview

Go deeper on allogeneic human umbilical cord tissue-derived mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogeneic human umbilical cord tissue-derived mesenchymal stem cells.

Explore the full profile